Abstract
Solitary fibrous tumor of the prostate (pSFT) is an exceptionally rare mesenchymal neoplasm. This study presents a new case report and the first systematic review of 74 published cases to establish diagnostic and management guidelines. (PROSPERO identifier: CRD420251004804).
Introduction
The prostate is predominantly associated with epithelial conditions such as adenocarcinoma or benign prostatic hyperplasia (BPH). However, the solitary fibrous tumor of the prostate (pSFT) represents a rare stromal challenge. Often referred to as the "great imitator," pSFT frequently mimics more common urological conditions, leading to significant diagnostic delays and management uncertainties. This paper, published in Frontiers in Oncology, provides a comprehensive roadmap for identifying this rare clinical entity.
Methodology and Data Selection
To better understand pSFT, researchers conducted a dual-track study involving a clinical case report of a 71-year-old male and a comprehensive systematic review. Following PRISMA guidelines, the team searched major databases including PubMed, Web of Science, Cochrane Library, and Embase for all recorded pSFT cases from database inception through October 2024.
The screening process identified 1,127 initial studies, which were eventually narrowed down to 40 studies encompassing 74 distinct cases (73 from literature plus the authors' new case).
Clinical Characteristics and the PSA "Red Herring"
Analysis of the 74 cases revealed a broad demographic range, with patients aged 21 to 89 (mean age 57.5). A critical finding for clinicians is the behavior of Prostate-Specific Antigen (PSA). In nearly all documented cases, PSA levels remained within the normal range despite the presence of large prostatic masses. This lack of biomarker elevation is a key diagnostic clue; a significant prostate mass accompanied by normal PSA should immediately trigger suspicion of a non-epithelial tumor like pSFT.
Diagnostic Insights: Imaging and Molecular Markers
The study identifies two primary pillars for accurate diagnosis:
- Imaging Fingerprint: Contrast-enhanced CT or MRI often reveals a "centripetal" enhancement pattern—continuous and gradual filling from the periphery toward the center—frequently bounded by a visible capsule.
- Molecular Signature: The expression of STAT6 in the nucleus and/or the presence of the NAB2-STAT6 fusion gene serves as the gold standard biomarker, offering approximately 97% sensitivity in distinguishing pSFT from other spindle-cell tumors.
Prognosis and Management
The systematic review found that 21.6% of pSFT cases were malignant. Interestingly, the size of the lesion did not significantly correlate with whether the tumor was benign or malignant, suggesting that biological behavior dictates prognosis more than bulk. There was a statistically significant difference in disease-free survival between benign/borderline and malignant pSFT (P=0.011).
Surgical resection, either through radical prostatectomy or enucleation, remains the primary treatment modality. Because pSFT typically shows low sensitivity to conventional radiotherapy and chemotherapy, achieving complete surgical margins is the most critical factor for preventing recurrence and ensuring long-term success.
Conclusion
As a rare mesenchymal tumor, pSFT requires a high index of clinical suspicion, particularly when imaging shows centripetal enhancement and PSA levels are normal. While surgery is effective, the high rate of initial misdiagnosis (23%) underscores the need for standardized reporting and the use of STAT6 immunohistochemistry. Future efforts should focus on global database collaboration to refine risk stratification models and improve preoperative biopsy accuracy.
Summary updated